Determination of Dabigatran in Human Plasma Samples

Abstract

The oral direct thrombin inhibitor dabigatran effectively prevents arterial and venous thromboembolism using fixed doses without the need for adjustment according to laboratory results. Dabigatran is eliminated from the circulation by ∼80% through the kidneys. However, the in vitro anticoagulant effect of dabigatran may be necessary to determine in special patient populations such as in the elderly, for renal impairment, before operations, bleeding or thrombotic episodes, and to monitor self-compliance. Several clotting and thrombin-specific chromogenic substrate assays are available to analyze the biological activity of dabigatran. All of them are prolonged in the presence of dabigatran. This article reports the effects of dabigatran on clinical routine assays and the potential usefulness for determination in special risk groups of patients when overdose or lack of compliance are suspected.

Keywords

dabigatran - Hemoclot assay - chromogenic assay - prothrombin-induced clotting time assay - Ecarin clotting time - prothrombin time - activated partial thromboplastin time

• References

• 1 Ansell J, Hirsh J, Hylek E , et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133 (6 Suppl) 160S-198S
• 2 Kearon C, Kahn SR, Agnelli G , et al. Antithrombotic Therapy for Venous Thromboembolic Disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133 (6) (Suppl) 454S-545S
• 3 Baker WL, Cios DA, Sander SD , et al. Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States. J Manag Care Pharm 2009; 15 (3) 244-252
• 4 Schulman S, Kearon C, Kakkar AK , et al; RE-COVER Study Group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361 (24) 2342-2352
• 5 Schulman S, Baanstra D, Eriksson H , et al. Dabigatran versus placebo for extended maintenance therapy of venous thromboembolism. J Thromb Haemost 2011 ; 9:(Suppl 2: Abstract O-MO-037)
• 6 Schulman S, Eriksson H, Goldhaber SZ , et al. Dabigatran or warfarin for extended maintenance therapy of venous thromboembolism. J Thromb Haemost 2011 ;9:(Suppl 2: Abstract O-TH-033)
• 7 Connolly SJ, Ezekowitz MD, Yusuf S , et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361 (12) 1139-1151
• 8 Mismetti P, Laporte S. New oral antithrombotics: a need for laboratory monitoring. J Thromb Haemost 2010; 8 (4) 621-626
• 9 Hauel NH, Nar H, Priepke H , et al. Structure-based design of novel potent nonpeptide thrombin inhibitors. J Med Chem 2002; 45 (9) 1757-1766
• 10 Kornalik F, Blomback B. Prothrombin activation induced by ecarin - a prothrombin converting enzyme from Echis carinatus venom. Thromb Res 1975; 6 (1) 57-63
• 11 Nowak G, Bucha E. Quantitative determination of hirudin in blood and body fluids. Semin Thromb Hemost 1996; 22 (2) 197-202
• 12 Poetzsch B, Hund S, Madlener K , et al. Monitoring of recombinant hirudin: Assessment of a plasma-based ecarin clotting time assay. Thromb Res 1997; 86 (5) 373-383
• 13 Fenyvesi T, Harenberg J, Weiss C , et al. Comparison of two different ecarin clotting time methods. J Thromb Thrombolysis 2005; 20 (1) 51-56
• 14 Schoeni R. The use of snake-venom derived compounds for new functional diagnostic test kits in the field of haemostasis. Pathophysiol Haemost Thromb 2005; 34 (4–5) 234-240
• 15 Calatzis A, Spannagl M, Gempeler-Messina P , et al. The prothrombinase-induced clotting time, a new technique for the monitoring of anticoagulants. Haemostasis 2000; 30 (Suppl 2) 172-174
• 16 Harenberg J, Giese C, Hagedorn A , et al. Determination of antithrombin-dependent factor Xa inhibitors by prothrombin-induced clotting time. Semin Thromb Hemost 2007; 33 (5) 503-507
• 17 Harder S, Parisius J, Picard-Willems B. Monitoring direct FXa-inhibitors and fondaparinux by Prothrombinase-induced Clotting Time (PiCT): relation to FXa-activity and influence of assay modifications. Thromb Res 2008; 123 (2) 396-403
• 18 van Ryn J, Stangier J, Haertter S , et al. Dabigatran etexilate–a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010; 103 (6) 1116-1127
• 19 Hori M, Connolly SJ, Ezekowitz MD , et al RE-LY Investigators. Efficacy and safety of dabigatran vs. warfarin in patients with atrial fibrillation-sub-analysis in Japanese population in RE-LY trial. Circ J 2011; 75 (4) 800-805
• 20 Liesenfeld KH, Lehr T, Dansirikul C , et al. A population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial. J Thromb Haemost 2011; 9 (11) 2168-2175
• 21 Fenyvesi T, Jörg I, Weiss C , et al. Effects of lepirudin, argatroban and melagatran and additional influence of phenprocoumon on ecarin clotting time. Thromb Res 2003; 111 (1–2) 89-94
• 22 Fenyvesi T, Jörg I, Harenberg J. Effect of phenprocoumon on monitoring of lepirudin, argatroban, melagatran and unfractionated heparin with the PiCT method. Pathophysiol Haemost Thromb 2002; 32 (4) 174-179